Biogen reports two-year Phase II data for diranersen in Alzheimer’s
The trial evaluated diranersen in 416 patients with mild cognitive impairment or mild dementia due to Alzheimer's.
A leading resource for the Pharmaceutical industry since 2002
The trial evaluated diranersen in 416 patients with mild cognitive impairment or mild dementia due to Alzheimer's.